Search

Your search keyword '"Onland-Moret, N. C."' showing total 175 results
Start Over Author "Onland-Moret, N. C."
175 results on '"Onland-Moret, N. C."'

8. Design and rationale of the NetherLands registry of invasive Coronary vasomotor Function Testing (NL-CFT)

Author

Crooijmans, C., Jansen, T. P.J., Konst, R. E., Woudstra, J., Appelman, Y., den Ruijter, H. M., Onland-Moret, N. C., Meeder, J. G., de Vos, A. M.J., Paradies, V., Woudstra, P., Sjauw, K. D., van 't Hof, A., Meuwissen, M., Winkler, P., Boersma, E., van de Hoef, T. P., Maas, A. H.E.M., Dimitriu-Leen, A. C., van Royen, N., Elias-Smale, S. E., Damman, P., Crooijmans, C., Jansen, T. P.J., Konst, R. E., Woudstra, J., Appelman, Y., den Ruijter, H. M., Onland-Moret, N. C., Meeder, J. G., de Vos, A. M.J., Paradies, V., Woudstra, P., Sjauw, K. D., van 't Hof, A., Meuwissen, M., Winkler, P., Boersma, E., van de Hoef, T. P., Maas, A. H.E.M., Dimitriu-Leen, A. C., van Royen, N., Elias-Smale, S. E., and Damman, P.

Abstract

Background: Angina without angiographic evidence of obstructive coronary artery disease (ANOCA) is a highly prevalent condition with insufficient pathophysiological knowledge and lack of evidence-based medical therapies. This affects ANOCA patients prognosis, their healthcare utilization and quality of life. In current guidelines, performing a coronary function test (CFT) is recommended to identify a specific vasomotor dysfunction endotype. The NetherLands registry of invasive Coronary vasomotor Function testing (NL-CFT) has been designed to collect data on ANOCA patients undergoing CFT in the Netherlands. Methods: The NL-CFT is a web-based, prospective, observational registry including all consecutive ANOCA patients undergoing clinically indicated CFT in participating centers throughout the Netherlands. Data on medical history, procedural data and (patient reported) outcomes are gathered. The implementation of a common CFT protocol in all participating hospitals promotes an equal diagnostic strategy and ensures representation of the entire ANOCA population. A CFT is performed after ruling out obstructive coronary artery disease. It comprises of both acetylcholine vasoreactivity testing as well as bolus thermodilution assessment of microvascular function. Optionally, continuous thermodilution or Doppler flow measurements can be performed. Participating centers can perform research using own data, or pooled data will be made available upon specific request via a secure digital research environment, after approval of a steering committee. Conclusion: NL-CFT will be an important registry by enabling both observational and registry based (randomized) clinical trials in ANOCA patients undergoing CFT.

Published
2023

10. Diastolic dysfunction and sex-specific progression to HFpEF: current gaps in knowledge and future directions

Author

Experimentele Afd. Cardiologie 1, Team Medisch, Circulatory Health, HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 3, Onderzoek Vrouw Hart & Vaatziekten, van Ommen, A M L N, Canto, E Dal, Cramer, Maarten J, Rutten, F H, Onland-Moret, N C, Ruijter, H M den, Experimentele Afd. Cardiologie 1, Team Medisch, Circulatory Health, HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 3, Onderzoek Vrouw Hart & Vaatziekten, van Ommen, A M L N, Canto, E Dal, Cramer, Maarten J, Rutten, F H, Onland-Moret, N C, and Ruijter, H M den

Published
2022

14. Additional file 3 of Evaluation of non-invasive imaging parameters in coronary microvascular disease: a systematic review

Author

Groepenhoff, F., Klaassen, R. G. M., Valstar, G. B., Bots, S. H., Onland-Moret, N. C., Den Ruijter, H. M., Leiner, T., and Eikendal, A. L. M.

Subjects
cardiovascular system, cardiovascular diseases, musculoskeletal system, circulatory and respiratory physiology
Abstract

Additional file 3: Table S2. Quantification of coronary microvascular dysfunction in CMR studies.

Published
2021
Full Text
View/download PDF

19. Correction to: Evaluation of non-invasive imaging parameters in coronary microvascular disease: a systematic review

Author

Onderzoek Vrouw Hart & Vaatziekten, Cardiovasculaire Epi Team 3, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Radiologie, Groepenhof, F, Klaassen, R G M, Valstar, G B, Bots, S H, Onland-Moret, N C, Ruijter, H M Den, Leiner, T, Eikendal, A L M, Onderzoek Vrouw Hart & Vaatziekten, Cardiovasculaire Epi Team 3, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Radiologie, Groepenhof, F, Klaassen, R G M, Valstar, G B, Bots, S H, Onland-Moret, N C, Ruijter, H M Den, Leiner, T, and Eikendal, A L M

Published
2021

20. Plasma Testosterone Levels and Atherosclerotic Plaque Gene Expression in Men With Advanced Atherosclerosis

Author

CDL Onderzoek Pasterkamp, Experimentele Afd. Cardiologie 1, Child Health, Infection & Immunity, Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, Cardiovasculaire Epi Team 3, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Centraal Diagnostisch Laboratorium, Onderzoek Vrouw Hart & Vaatziekten, Groepenhoff, Floor, Diez Benavente, Ernest, Boltjes, Arjan, Timmerman, Nathalie, Waissi, Farahnaz, Hartman, Robin J G, Onland-Moret, N C, Pasterkamp, Gerard, Den Ruijter, Hester, CDL Onderzoek Pasterkamp, Experimentele Afd. Cardiologie 1, Child Health, Infection & Immunity, Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, Cardiovasculaire Epi Team 3, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Centraal Diagnostisch Laboratorium, Onderzoek Vrouw Hart & Vaatziekten, Groepenhoff, Floor, Diez Benavente, Ernest, Boltjes, Arjan, Timmerman, Nathalie, Waissi, Farahnaz, Hartman, Robin J G, Onland-Moret, N C, Pasterkamp, Gerard, and Den Ruijter, Hester

Published
2021

21. Evaluation of non-invasive imaging parameters in coronary microvascular disease: a systematic review

Author

CDL Onderzoek Pasterkamp, Experimentele Afd. Cardiologie 1, Onderzoek Vrouw Hart & Vaatziekten, Cardiovasculaire Epi Team 3, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Researchgr. Cardiovasculaire Radiologie, Groepenhoff, F, Klaassen, R G M, Valstar, G B, Bots, S H, Onland-Moret, N C, Den Ruijter, H M, Leiner, T, Eikendal, A L M, CDL Onderzoek Pasterkamp, Experimentele Afd. Cardiologie 1, Onderzoek Vrouw Hart & Vaatziekten, Cardiovasculaire Epi Team 3, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Researchgr. Cardiovasculaire Radiologie, Groepenhoff, F, Klaassen, R G M, Valstar, G B, Bots, S H, Onland-Moret, N C, Den Ruijter, H M, Leiner, T, and Eikendal, A L M

Published
2021

22. Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events

Author

Leusink, M, Onland-Moret, N C, Asselbergs, F W, Ding, B, Kotti, S, van Zuydam, N R, Papp, A C, Danchin, N, Donnelly, L, Morris, A D, Chasman, D I, Doevendans, P AFM, Klungel, O H, Ridker, P M, van Gilst, W H, Simon, T, Nyberg, F, Palmer, C NA, Sadee, W, van der Harst, P, de Bakker, P IW, de Boer, A, Verstuyft, C, and Maitland-van der Zee, A H

Published
2014
Full Text
View/download PDF

24. Vasomotor menopausal symptoms and cardiovascular disease risk in midlife: A longitudinal study

Author

Cardiovasculaire Epi Team 1, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 3, JC onderzoeksprogramma Kanker, Cardiovasculaire Epidemiologie, Dam, V., Dobson, A. J., Onland-Moret, N. C., van der Schouw, Y. T., Mishra, G. D., Cardiovasculaire Epi Team 1, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 3, JC onderzoeksprogramma Kanker, Cardiovasculaire Epidemiologie, Dam, V., Dobson, A. J., Onland-Moret, N. C., van der Schouw, Y. T., and Mishra, G. D.

Published
2020

27. Age at Menarche in Relation to Adult Height: The EPIC Study

Author

Onland-Moret, N. C., Peeters, P. H. M., van Gils, C. H., Clavel-Chapelon, F., Key, T., Tjønneland, A., Trichopoulou, A., Kaaks, R., Manjer, J., Panico, S., Palli, D., Tehard, B., Stoikidou, M., Bueno-De-Mesquita, H. B., Boeing, H., Overvad, K., Lenner, P., Quirós, J. R., Chirlaque, M. D., Miller, A. B., Khaw, K. T., and Riboli, E.

Published
2005

31. Adult height, coronary heart disease and stroke : A multi-locus Mendelian randomization meta-analysis

Author

Nüesch, Eveline, Dale, Caroline, Palmer, Tom M., White, Jon, Keating, Brendan J., van Iperen, Erik P A, Goel, Anuj, Padmanabhan, Sandosh, Asselbergs, F. W., Verschuren, W. M., Wijmenga, C., Van der Schouw, Y. T., Onland-Moret, N. C., Lange, Leslie A., Hovingh, G. K., Sivapalaratnam, Suthesh, Morris, Richard W., Whincup, Peter H., Wannamethe, Goya S., Gaunt, Tom R., Ebrahim, Shah, Steel, Laura, Nair, Nikhil, Reiner, Alexander P., Kooperberg, Charles, Wilson, James F., Bolton, Jennifer L., McLachlan, Stela, Price, Jacqueline F., Strachan, Mark W J, Robertson, Christine M., Kleber, Marcus E., Delgado, Graciela, März, Winfried, Melander, Olle, Dominiczak, Anna F., Farrall, Martin, Watkins, Hugh, Leusink, Maarten, Maitland-van der Zee, Anke H., de Groot, Mark C H, Dudbridge, Frank, Hingorani, Aroon, Ben-Shlomo, Yoav, Lawlor, Debbie A., Amuzu, A., Caufield, M., Cavadino, A., Cooper, J., Davies, T. L., Day, I. N., Drenos, F., Engmann, J., Finan, C., Giambartolomei, C., Hardy, R., Humphries, S. E., Hypponen, E., Kivimaki, M., Kuh, D., Kumari, M., Ong, K., Plagnol, V., Power, C., Richards, M., Shah, S., Shah, T., Sofat, R., Talmud, P. J., Wareham, N., Warren, H., Whittaker, J. C., Wong, A., Zabaneh, D., Smith, George Davey, Wells, Jonathan C., Leon, David A., Holmes, Michael V., and Casas, Juan P.

Subjects
Medicine(all), procedure, Epidemiology, alleles, Journal Article, body mass index, cerebrovascular accident, triglycerides
Abstract

© The Author 2015; all rights reserved. Background: We investigated causal effect of completed growth, measured by adult height, on coronary heart disease (CHD), stroke and cardiovascular traits, using instrumental variable (IV) Mendelian randomization meta-analysis. Methods: We developed an allele score based on 69 single nucleotide polymorphisms (SNPs) associated with adult height, identified by the IBCCardioChip, and used it for IV analysis against cardiovascular risk factors and events in 21 studies and 60 028 participants. IV analysis on CHD was supplemented by summary data from 180 height-SNPs from the GIANT consortium and their corresponding CHD estimates derived from CARDIoGRAMplusC4D. Results: IV estimates from IBCCardioChip and GIANT-CARDIoGRAMplusC4D showed that a 6.5-cm increase in height reduced the odds of CHD by 10% [odds ratios 0.90; 95% confidence intervals (CIs): 0.78 to 1.03 and 0.85 to 0.95, respectively],which agrees with the estimate from the Emerging Risk Factors Collaboration (hazard ratio 0.93; 95% CI: 0.91 to 0.94). IV analysis revealed no association with stroke (odds ratio 0.97; 95% CI: 0.79 to 1.19). IV analysis showed that a 6.5-cm increase in height resulted in lower levels of body mass index (P < 0.001), triglycerides (P < 0.001), non high-density (non-HDL) cholesterol (P < 0.001), C-reactive protein (P = 0.042), and systolic blood pressure (P = 0.064) and higher levels of forced expiratory volume in 1 s and forced vital capacity (P < 0.001 for both). Conclusions: Taller individuals have a lower risk of CHD with potential explanations being that taller people have a better lung function and lower levels of body mass index, cholesterol and blood pressure.

Published
2016

33. Erratum to: Unraveling the associations of age and menopause with cardiovascular risk factors in a large population-based study

Author

Circulatory Health, MS VPG/Gynaecologie, Cardiovasculaire Epi Team 1, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 3, Brain, Cancer, JC onderzoeksprogramma Kanker, Biostatistiek Onderzoek, Child Health, JC onderzoeksprogramma Methodologie, JC onderzoeksprogramma Infectieziekten, Infection & Immunity, Cardiovasculaire Epidemiologie, de Kat, A C, Dam, V, Onland-Moret, N C, Eijkemans, M J C, Broekmans, F J M, van der Schouw, Y T, Circulatory Health, MS VPG/Gynaecologie, Cardiovasculaire Epi Team 1, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 3, Brain, Cancer, JC onderzoeksprogramma Kanker, Biostatistiek Onderzoek, Child Health, JC onderzoeksprogramma Methodologie, JC onderzoeksprogramma Infectieziekten, Infection & Immunity, Cardiovasculaire Epidemiologie, de Kat, A C, Dam, V, Onland-Moret, N C, Eijkemans, M J C, Broekmans, F J M, and van der Schouw, Y T

Published
2017

34. Unraveling the associations of age and menopause with cardiovascular risk factors in a large population-based study

Author

Circulatory Health, MS VPG/Gynaecologie, Cardiovasculaire Epi Team 1, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 3, Brain, Cancer, JC onderzoeksprogramma Kanker, Biostatistiek Onderzoek, Child Health, JC onderzoeksprogramma Methodologie, JC onderzoeksprogramma Infectieziekten, Infection & Immunity, Cardiovasculaire Epidemiologie, de Kat, A C, Dam, V, Onland-Moret, N C, Eijkemans, M J C, Broekmans, F J M, van der Schouw, Y T, Circulatory Health, MS VPG/Gynaecologie, Cardiovasculaire Epi Team 1, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 3, Brain, Cancer, JC onderzoeksprogramma Kanker, Biostatistiek Onderzoek, Child Health, JC onderzoeksprogramma Methodologie, JC onderzoeksprogramma Infectieziekten, Infection & Immunity, Cardiovasculaire Epidemiologie, de Kat, A C, Dam, V, Onland-Moret, N C, Eijkemans, M J C, Broekmans, F J M, and van der Schouw, Y T

Published
2017

37. Adult height, coronary heart disease and stroke:a multi-locus Mendelian randomization meta-analysis

Author

Nüesch, Eveline, Dale, Caroline, Palmer, Tom M, White, Jon, Keating, Brendan J, van Iperen, Erik Pa, Goel, Anuj, Padmanabhan, Sandosh, Asselbergs, Folkert W, Verschuren, W M, Wijmenga, C, Van der Schouw, Y T, Onland-Moret, N C, Lange, Leslie A, Hovingh, G K, Sivapalaratnam, Suthesh, Morris, Richard W, Whincup, Peter H, Wannamethe, Goya S, Gaunt, Tom R, Ebrahim, Shah, Steel, Laura, Nair, Nikhil, Reiner, Alexander P, Kooperberg, Charles, Strachan, Mark Wj, Robertson, Christine M, Kleber, Marcus E, Delgado, Graciela, März, Winfried, Melander, Olle, Dominiczak, Anna F, Farrall, Martin, Watkins, Hugh, Leusink, Maarten, Maitland-van der Zee, Anke H, de Groot, Mark Ch, Dudbridge, Frank, Hingorani, Aroon, Ben-Shlomo, Yoav, Lawlor, Debbie A, Amuzu, A, Caufield, M, Cavadino, A, Cooper, J, Davies, T L, Wilson, James F, Bolton, Jennifer, McLachlan, Stela, and Price, Jacqueline F

Abstract

BACKGROUND: We investigated causal effect of completed growth, measured by adult height, on coronary heart disease (CHD), stroke and cardiovascular traits, using instrumental variable (IV) Mendelian randomization meta-analysis.METHODS: We developed an allele score based on 69 single nucleotide polymorphisms (SNPs) associated with adult height, identified by the IBCCardioChip, and used it for IV analysis against cardiovascular risk factors and events in 21 studies and 60 028 participants. IV analysis on CHD was supplemented by summary data from 180 height-SNPs from the GIANT consortium and their corresponding CHD estimates derived from CARDIoGRAMplusC4D.RESULTS: IV estimates from IBCCardioChip and GIANT-CARDIoGRAMplusC4D showed that a 6.5-cm increase in height reduced the odds of CHD by 10% [odds ratios 0.90; 95% confidence intervals (CIs): 0.78 to 1.03 and 0.85 to 0.95, respectively],which agrees with the estimate from the Emerging Risk Factors Collaboration (hazard ratio 0.93; 95% CI: 0.91 to 0.94). IV analysis revealed no association with stroke (odds ratio 0.97; 95% CI: 0.79 to 1.19). IV analysis showed that a 6.5-cm increase in height resulted in lower levels of body mass index (P CONCLUSIONS: Taller individuals have a lower risk of CHD with potential explanations being that taller people have a better lung function and lower levels of body mass index, cholesterol and blood pressure.

Published
2015

38. Menopausal hormone use and ovarian cancer risk : individual participant meta-analysis of 52 epidemiological studies

Author

Gapstur, S. M., Patel, A. V., Banks, E., Dal Maso, L., Talamini, R., Chetrit, A., Hirsh-Yechezkel, G., Lubin, F., Sadetzki, S., Beral, V., Bull, D., Cairns, B., Crossley, B., Gaitskell, K., Goodill, A., Green, J., Hermon, C., Key, T., Moser, K., Reeves, G., Sitas, F., Collins, R., Peto, R., Gonzalez, C. A., Lee, N., Marchbanks, P., Ory, H. W., Peterson, H. B., Wingo, P. A., Martin, N., Silpisornkosol, S., Theetranont, C., Boosiri, B., Chutivongse, S., Jimakorn, P., Virutamasen, P., Wongsrichanalai, C., Goodman, M. T., Lidegaard, O., Kjaer, S. K., Morch, L. S., Tjonneland, A., Byers, T., Rohan, T., Mosgaard, B., Vessey, M., Yeates, D., Onland-Moret, N. C., Peeters, P. H. M., and Collaborative Grp Epidemiological

Subjects
WOMEN, HEALTH, THERAPY
Abstract

Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with Interpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users.

Published
2015

39. Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort

Author

Ose, J. Fortner, R. T. Schock, H. Peeters, P. H. and Onland-Moret, N. C. Bueno-de-Mesquita, H. B. Weiderpass, E. and Gram, I. T. Overvad, K. Tjonneland, A. Dossus, L. and Fournier, A. Baglietto, L. Trichopoulou, A. Benetou, V. and Trichopoulos, D. Boeing, H. Masala, G. Krogh, V. and Matiello, A. Tumino, R. Popovic, M. Obon-Santacana, M. and Larranaga, N. Ardanaz, E. Sanchez, M-J Menendez, V. and Chirlaque, M-D Travis, R. C. Khaw, K-T Braendstedt, J. and Idahl, A. Lundin, E. Rinaldi, S. Kuhn, E. Romieu, I. and Gunter, M. J. Merritt, M. A. Riboli, E. Kaaks, R.

Subjects
endocrine system diseases, female genital diseases and pregnancy complications
Abstract

Background: Prospective studies on insulin-like growth factor I (IGF-I) and epithelial ovarian cancer (EOC) risk are inconclusive. Data suggest risk associations vary by tumour characteristics. Methods: We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) to evaluate IGF-I concentrations and EOC risk by tumour characteristics (n = 565 cases). Multivariable conditional logistic regression models were used to estimate associations. Results: We observed no association between IGF-I and EOC overall or by tumour characteristics. Conclusions: In the largest prospective study to date was no association between IGF-I and EOC risk. Pre-diagnostic serum IGF-I concentrations may not influence EOC risk.

Published
2015

40. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

Author

Gapstur, S. M. Patel, A. V. Banks, E. Dal Maso, L. and Talamini, R. Chetrit, A. Hirsh-Yechezkel, G. Lubin, F. and Sadetzki, S. Beral, V. Bull, D. Cairns, B. Crossley, B. and Gaitskell, K. Goodill, A. Green, J. Hermon, C. Key, T. Moser, K. Reeves, G. Sitas, F. Collins, R. Peto, R. Gonzalez, C. A. Lee, N. Marchbanks, P. Ory, H. W. and Peterson, H. B. Wingo, P. A. Martin, N. Silpisornkosol, S. and Theetranont, C. Boosiri, B. Chutivongse, S. Jimakorn, P. and Virutamasen, P. Wongsrichanalai, C. Goodman, M. T. and Lidegaard, O. Kjaer, S. K. Morch, L. S. Tjonneland, A. and Byers, T. Rohan, T. Mosgaard, B. Vessey, M. Yeates, D. and Freudenheim, J. L. Titus, L. J. Chang-Claude, J. Kaaks, R. Anderson, K. E. Lazovich, D. Robien, K. Hampton, J. and Newcomb, P. A. Rossing, M. A. Thomas, D. B. Weiss, N. S. and Lokkegaard, E. Riboli, E. Clavel-Chapelon, F. Cramer, D. and Hankinson, S. E. Tamimi, R. M. Tworoger, S. S. and Franceschi, S. La Vecchia, C. Negri, E. Adami, H. O. and Magnusson, C. Riman, T. Weiderpass, E. Wolk, A. and Schouten, L. J. van den Brandt, P. A. Chantarakul, N. and Koetsawang, S. Rachawat, D. Palli, D. Black, A. Brinton, L. A. Freedman, D. M. Hartge, P. Hsing, A. W. Jnr, J. V. Lacey Lissowska, J. Hoover, R. N. Schairer, C. Babb, C. and Urban, M. Graff-Iversen, S. Selmer, R. Bain, C. J. and Green, A. C. Purdie, D. M. Siskind, V. Webb, P. M. and Moysich, K. McCann, S. E. Hannaford, P. Kay, C. Binns, C. W. Lee, A. H. Zhang, M. Ness, R. B. Nasca, P. and Coogan, P. F. Palmer, J. R. Rosenberg, L. Whittemore, A. and Katsouyanni, K. Trichopoulou, A. Trichopoulos, D. Tzonou, A. and Dabancens, A. Martinez, L. Molina, R. Salas, O. and Lurie, G. Carney, M. E. Wilkens, L. R. Hartman, L. and Manjer, J. Olsson, H. Kumle, M. Grisso, J. A. Morgan, M. and Wheeler, J. E. Edwards, R. P. Kelley, J. L. Modugno, F. and Onland-Moret, N. C. Peeters, P. H. M. Casagrande, J. and Pike, M. C. Wu, A. H. Canfell, K. Miller, A. B. Gram, I. T. Lund, E. McGowan, L. Shu, X. O. Zheng, W. Farley, T. M. M. Holck, S. Meirik, O. Risch, H. A. Collaborative Grp Epidemiological

Abstract

Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with

Published
2015

41. Genetic variation in uncontrolled childhood asthma despite ICS treatment

Author

Leusink, M., Vijverberg, S. J H, Koenderman, L., Raaijmakers, J. A M, de Jongste, J. C., Sterk, P. J., Duiverman, E. J., Onland-Moret, N. C., Postma, D. S., de Boer, A., de Bakker, P. I W, Koppelman, G. H., Maitland-van der Zee, A. H., Leusink, M., Vijverberg, S. J H, Koenderman, L., Raaijmakers, J. A M, de Jongste, J. C., Sterk, P. J., Duiverman, E. J., Onland-Moret, N. C., Postma, D. S., de Boer, A., de Bakker, P. I W, Koppelman, G. H., and Maitland-van der Zee, A. H.

Published
2016

42. Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis

Author

Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology and Clinical Pharmacology, UU LEG Research USE Tjalling C. Koopmans Institute, Nüesch, Eveline, Dale, Caroline, Palmer, Tom M, White, Jon, Keating, Brendan J, van Iperen, Erik Pa, Goel, Anuj, Padmanabhan, Sandosh, Asselbergs, Folkert W, Verschuren, W M, Wijmenga, C, Van der Schouw, Y T, Onland-Moret, N C, Lange, Leslie A, Hovingh, G K, Sivapalaratnam, Suthesh, Morris, Richard W, Whincup, Peter H, Wannamethe, Goya S, Gaunt, Tom R, Ebrahim, Shah, Steel, Laura, Nair, Nikhil, Reiner, Alexander P, Kooperberg, Charles, Wilson, James F, Bolton, Jennifer L, McLachlan, Stela, Price, Jacqueline F, Strachan, Mark Wj, Robertson, Christine M, Kleber, Marcus E, Delgado, Graciela, März, Winfried, Melander, Olle, Dominiczak, Anna F, Farrall, Martin, Watkins, Hugh, Leusink, Maarten, Maitland-van der Zee, Anke H, de Groot, Mark Ch, Dudbridge, Frank, Hingorani, Aroon, Ben-Shlomo, Yoav, Lawlor, Debbie A, Amuzu, A, Caufield, M, Cavadino, A, Cooper, J, Wong, A, EPIC-Netherland Investigators, Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology and Clinical Pharmacology, UU LEG Research USE Tjalling C. Koopmans Institute, Nüesch, Eveline, Dale, Caroline, Palmer, Tom M, White, Jon, Keating, Brendan J, van Iperen, Erik Pa, Goel, Anuj, Padmanabhan, Sandosh, Asselbergs, Folkert W, Verschuren, W M, Wijmenga, C, Van der Schouw, Y T, Onland-Moret, N C, Lange, Leslie A, Hovingh, G K, Sivapalaratnam, Suthesh, Morris, Richard W, Whincup, Peter H, Wannamethe, Goya S, Gaunt, Tom R, Ebrahim, Shah, Steel, Laura, Nair, Nikhil, Reiner, Alexander P, Kooperberg, Charles, Wilson, James F, Bolton, Jennifer L, McLachlan, Stela, Price, Jacqueline F, Strachan, Mark Wj, Robertson, Christine M, Kleber, Marcus E, Delgado, Graciela, März, Winfried, Melander, Olle, Dominiczak, Anna F, Farrall, Martin, Watkins, Hugh, Leusink, Maarten, Maitland-van der Zee, Anke H, de Groot, Mark Ch, Dudbridge, Frank, Hingorani, Aroon, Ben-Shlomo, Yoav, Lawlor, Debbie A, Amuzu, A, Caufield, M, Cavadino, A, Cooper, J, Wong, A, and EPIC-Netherland Investigators

Published
2016

43. Adult height, coronary heart disease and stroke: A multi-locus Mendelian randomization meta-analysis

Author

Cardiologie, Circulatory Health, Team Medisch, Public Health Epidemiologie, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 3, Brain, Cancer, JC onderzoeksprogramma Kanker, CDL Upod, Other research (not in main researchprogram), Nüesch, Eveline, Dale, Caroline, Palmer, Tom M., White, Jon, Keating, Brendan J., van Iperen, Erik P A, Goel, Anuj, Padmanabhan, Sandosh, Asselbergs, F. W., Verschuren, W. M., Wijmenga, C., Van der Schouw, Y. T., Onland-Moret, N. C., Lange, Leslie A., Hovingh, G. K., Sivapalaratnam, Suthesh, Morris, Richard W., Whincup, Peter H., Wannamethe, Goya S., Gaunt, Tom R., Ebrahim, Shah, Steel, Laura, Nair, Nikhil, Reiner, Alexander P., Kooperberg, Charles, Wilson, James F., Bolton, Jennifer L., McLachlan, Stela, Price, Jacqueline F., Strachan, Mark W J, Robertson, Christine M., Kleber, Marcus E., Delgado, Graciela, März, Winfried, Melander, Olle, Dominiczak, Anna F., Farrall, Martin, Watkins, Hugh, Leusink, Maarten, Maitland-van der Zee, Anke H., de Groot, Mark C H, Dudbridge, Frank, Hingorani, Aroon, Ben-Shlomo, Yoav, Lawlor, Debbie A., Amuzu, A., Caufield, M., Cavadino, A., Cooper, J., Davies, T. L., Day, I. N., Drenos, F., Engmann, J., Finan, C., Giambartolomei, C., Hardy, R., Humphries, S. E., Hypponen, E., Kivimaki, M., Kuh, D., Kumari, M., Ong, K., Plagnol, V., Power, C., Richards, M., Shah, S., Shah, T., Sofat, R., Talmud, P. J., Wareham, N., Warren, H., Whittaker, J. C., Wong, A., Zabaneh, D., Smith, George Davey, Wells, Jonathan C., Leon, David A., Holmes, Michael V., Casas, Juan P., Cardiologie, Circulatory Health, Team Medisch, Public Health Epidemiologie, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 3, Brain, Cancer, JC onderzoeksprogramma Kanker, CDL Upod, Other research (not in main researchprogram), Nüesch, Eveline, Dale, Caroline, Palmer, Tom M., White, Jon, Keating, Brendan J., van Iperen, Erik P A, Goel, Anuj, Padmanabhan, Sandosh, Asselbergs, F. W., Verschuren, W. M., Wijmenga, C., Van der Schouw, Y. T., Onland-Moret, N. C., Lange, Leslie A., Hovingh, G. K., Sivapalaratnam, Suthesh, Morris, Richard W., Whincup, Peter H., Wannamethe, Goya S., Gaunt, Tom R., Ebrahim, Shah, Steel, Laura, Nair, Nikhil, Reiner, Alexander P., Kooperberg, Charles, Wilson, James F., Bolton, Jennifer L., McLachlan, Stela, Price, Jacqueline F., Strachan, Mark W J, Robertson, Christine M., Kleber, Marcus E., Delgado, Graciela, März, Winfried, Melander, Olle, Dominiczak, Anna F., Farrall, Martin, Watkins, Hugh, Leusink, Maarten, Maitland-van der Zee, Anke H., de Groot, Mark C H, Dudbridge, Frank, Hingorani, Aroon, Ben-Shlomo, Yoav, Lawlor, Debbie A., Amuzu, A., Caufield, M., Cavadino, A., Cooper, J., Davies, T. L., Day, I. N., Drenos, F., Engmann, J., Finan, C., Giambartolomei, C., Hardy, R., Humphries, S. E., Hypponen, E., Kivimaki, M., Kuh, D., Kumari, M., Ong, K., Plagnol, V., Power, C., Richards, M., Shah, S., Shah, T., Sofat, R., Talmud, P. J., Wareham, N., Warren, H., Whittaker, J. C., Wong, A., Zabaneh, D., Smith, George Davey, Wells, Jonathan C., Leon, David A., Holmes, Michael V., and Casas, Juan P.

Published
2016

44. Genetic variation in uncontrolled childhood asthma despite ICS treatment

Author

Experimentele Afdeling Longziekten, Cancer, Infection & Immunity, Cardiovasculaire Epi Team 3, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, JC onderzoeksprogramma Kanker, CMM Groep Kaaij, Brain, JC onderzoeksprogramma Methodologie, Leusink, M., Vijverberg, S. J H, Koenderman, L., Raaijmakers, J. A M, de Jongste, J. C., Sterk, P. J., Duiverman, E. J., Onland-Moret, N. C., Postma, D. S., de Boer, A., de Bakker, P. I W, Koppelman, G. H., Maitland-van der Zee, A. H., Experimentele Afdeling Longziekten, Cancer, Infection & Immunity, Cardiovasculaire Epi Team 3, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, JC onderzoeksprogramma Kanker, CMM Groep Kaaij, Brain, JC onderzoeksprogramma Methodologie, Leusink, M., Vijverberg, S. J H, Koenderman, L., Raaijmakers, J. A M, de Jongste, J. C., Sterk, P. J., Duiverman, E. J., Onland-Moret, N. C., Postma, D. S., de Boer, A., de Bakker, P. I W, Koppelman, G. H., and Maitland-van der Zee, A. H.

Published
2016

45. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data

Author

Holmes, M. V., Dale, C. E., Zuccolo, L., Silverwood, R. J., Guo, Y., Ye, Z., Prieto-Merino, D., Dehghan, A., Trompet, S., Wong, A., Cavadino, A., Drogan, D., Padmanabhan, S., Li, S., Yesupriya, A., Leusink, M., Sundstrom, J., Hubacek, J. A., Pikhart, H., Swerdlow, D. I., Panayiotou, A. G., Borinskaya, S. A., Finan, C., Shah, S., Kuchenbaecker, K. B., Shah, T., Engmann, J., Folkersen, L., Eriksson, P., Ricceri, F., Melander, O., Sacerdote, C., Gamble, D. M., Rayaprolu, S., Ross, O. A., McLachlan, S., Vikhireva, O., Sluijs, I., Scott, R. A., Adamkova, V., Flicker, L., Bockxmeer, F. M. v., Power, C., Marques-Vidal, P., Meade, T., Marmot, M. G., Ferro, J. M., Paulos-Pinheiro, S., Humphries, S. E., Talmud, P. J., Leach, I. M., Verweij, N., Linneberg, A., Skaaby, T., Doevendans, P. A., Cramer, M. J., Harst, P. v. d., Klungel, O. H., Dowling, N. F., Dominiczak, A. F., Kumari, M., Nicolaides, A. N., Weikert, C., Boeing, H., Ebrahim, S., Gaunt, T. R., Price, J. F., Lannfelt, L., Peasey, A., Kubinova, R., Pajak, A., Malyutina, S., Voevoda, M. I., Tamosiunas, A., Maitland-van der Zee, A. H., Norman, P. E., Hankey, G. J., Bergmann, M. M., Hofman, A., Franco, O. H., Cooper, J., Palmen, J., Spiering, W., Jong, P. A. d., Kuh, D., Hardy, R., Uitterlinden, A. G., Ikram, M. A., Ford, I., Hypponen, E., Almeida, O. P., Wareham, N. J., Khaw, K.-T., Hamsten, A., Husemoen, L. L. N., Tjonneland, A., Tolstrup, J. S., Rimm, E., Beulens, J. W. J., Verschuren, W. M. M., Onland-Moret, N. C., Hofker, M. H., Wannamethee, S. G., Whincup, P. H., Morris, R., Vicente, A. M., Watkins, H., Farrall, M., Jukema, J. W., Meschia, J., Cupples, L. A., Sharp, S. J., Fornage, M., Kooperberg, C., LaCroix, A. Z., Dai, J. Y., Lanktree, M. B., Siscovick, D. S., Jorgenson, E., Spring, B., Coresh, J., Li, Y. R., Buxbaum, S. G., Schreiner, P. J., Ellison, R. C., Tsai, M. Y., Patel, S. R., Redline, S., Johnson, A. D., Hoogeveen, R. C., Hakonarson, H., Rotter, J. I., Boerwinkle, E., Bakker, P. I. W. d., Kivimaki, M., Asselbergs, F. W., Sattar, N., Lawlor, D. A., Whittaker, J., Davey Smith, G., Mukamal, K., Psaty, B. M., Wilson, J. G., Lange, L. A., Hamidovic, A., Hingorani, A. D., Nordestgaard, B. G., Bobak, M., Leon, D. A., Langenberg, C., Palmer, T. M., Reiner, A. P., Keating, B. J., Dudbridge, F., Casas, J. P., Repositório da Universidade de Lisboa, and InterAct Consortium

Subjects
Adult, Genetic Markers, Male, Models, Statistical, Alcohol Drinking, Genotype, Alcohol Dehydrogenase, Coronary Disease, Mendelian Randomization Analysis, Middle Aged, Polymorphism, Single Nucleotide, Stroke, Aged, Alcohol Dehydrogenase/genetics, Alcohol Drinking/adverse effects, Alcohol Drinking/genetics, Biomarkers/blood, Coronary Disease/blood, Coronary Disease/etiology, Coronary Disease/genetics, Female, Humans, Stroke/blood, Stroke/etiology, Stroke/genetics, Cardiac and Cardiovascular Systems, Biomarkers
Abstract

Copyright © 2014, BMJ Publishing Group Ltd. This is an Open Access article distributed in accordance with the Creative CommonsAttribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute,remix, adapt, build upon this work non-commercially, and license their derivative workson different terms, provided the original work is properly cited and the use isnon-commercial. See: http://creativecommons.org/licenses/by-nc/3., Objective: To use the rs1229984 variant in the alcohol dehydrogenase 1B gene (ADH1B) as an instrument to investigate the causal role of alcohol in cardiovascular disease. Design: Mendelian randomisation meta-analysis of 56 epidemiological studies. Participants: 261 991 individuals of European descent, including 20 259 coronary heart disease cases and 10 164 stroke events. Data were available on ADH1B rs1229984 variant, alcohol phenotypes, and cardiovascular biomarkers. Main outcome measures: Odds ratio for coronary heart disease and stroke associated with the ADH1B variant in all individuals and by categories of alcohol consumption. Results: Carriers of the A-allele of ADH1B rs1229984 consumed 17.2% fewer units of alcohol per week (95% confidence interval 15.6% to 18.9%), had a lower prevalence of binge drinking (odds ratio 0.78 (95% CI 0.73 to 0.84)), and had higher abstention (odds ratio 1.27 (1.21 to 1.34)) than non-carriers. Rs1229984 A-allele carriers had lower systolic blood pressure (-0.88 (-1.19 to -0.56) mm Hg), interleukin-6 levels (-5.2% (-7.8 to -2.4%)), waist circumference (-0.3 (-0.6 to -0.1) cm), and body mass index (-0.17 (-0.24 to -0.10) kg/m(2)). Rs1229984 A-allele carriers had lower odds of coronary heart disease (odds ratio 0.90 (0.84 to 0.96)). The protective association of the ADH1B rs1229984 A-allele variant remained the same across all categories of alcohol consumption (P=0.83 for heterogeneity). Although no association of rs1229984 was identified with the combined subtypes of stroke, carriers of the A-allele had lower odds of ischaemic stroke (odds ratio 0.83 (0.72 to 0.95)). Conclusions: Individuals with a genetic variant associated with non-drinking and lower alcohol consumption had a more favourable cardiovascular profile and a reduced risk of coronary heart disease than those without the genetic variant. This suggests that reduction of alcohol consumption, even for light to moderate drinkers, is beneficial for cardiovascular health.

Published
2014

46. The Significance of Fragile X Mental Retardation Gene 1 CGG Repeat Sizes in the Normal and Intermediate Range in Women With Primary Ovarian Insufficiency EDITORIAL COMMENT

Author

Voorhuis, M., Onland-Moret, N. C., Janse, F., van Amstel, H. K. Ploos, Goverde, A. J., Lambalk, C. B., Laven, J. S. E., van der Schouw, Y. T., Broekmans, F. J. M., Fauser, B. C. J. M., Obstetrics and gynaecology, ICaR - Ischemia and repair, RS: GROW - Developmental Biology, and RS: GROW - R4 - Reproductive and Perinatal Medicine

Abstract

Primary ovarian insufficiency (POI) refers to the cessation of menses before the age of 40 years and occurs in 1% to 2% of women. The specific cause of POI is unknown in the majority of cases. Known causes include gene mutations of fragile X mental retardation 1 (FMR1), a gene located on the X chromosome. This gene codes for a protein essential for normal cognitive development and female reproductive function. FMR1 contains a CCG trinucleotide segment in an untranslated region of its DNA that is repeated less than 45 times in normal individuals (normal range of repeats). Mutation of FMR1 results in abnormal expansion of an unstable CGG triplet, leading to impaired cognitive and reproductive function. Between 55 and 200 CCG repeats is called premutation; affected individuals with premutation are at risk for POI and further expansion of repeats in subsequent generations. People with 45 to 54 CCG repeats (intermediate range of repeats) are considered to be at borderline risk for POI and further expansion of repeats. This case-control study was designed to determine whether the risk of POI is associated with CGG repeat length of normal and intermediate range (up to 55 repeats) in a large cohort of Dutch women with idiopathic POI. The second aim of the study was to examine a possible association between the number of CGG repeats and age at first manifestation of POI as a measurement for the severity of POI. The study population was composed of 375 well-phenotyped Dutch women diagnosed with POI; control subjects were 3368 women with natural menopause at 40 years or older. The FMR1 CGG repeat number was determined by polymerase chain reaction amplification of DNA extracted from blood samples drawn from each patient. Fisher exact test was used to assess the prevalence of intermediate-size CGG repeats in POI cases and control subjects. Analysis of variance tested differences in mean CGG repeat lengths on alleles 1 and 2 between POI cases and control subjects. Allele 1 has the lowest triple repeat number, and allele 2 has the highest triple repeat number. There was no significant difference between POI cases and control subjects in the frequency of intermediate-size CGG repeats on allele 2 (POI 2.7 vs control subjects 3.8%; the odds ratio was 0.72, with a 95% confidence interval of 0.38-1.39; P = 0.38). Linear regression analysis showed no association between the number of CGG repeats and age at first POI manifestation ( = 20.019, P = 0.72). These data suggest that intermediate-size CGG repeats are not associated with risk of POI. Therefore, evaluation of normal and intermediate FMR1 repeat size appears to be of little or no value in the diagnostic workup of women affected by POI or in the prognostic assessment of women at risk of developing POI. Reasons for caution in interpreting these results are as follows: (1) FMR1 CGG repeat lengths in POI cases and control subjects were genotyped in 2 different laboratories; technical differences could have affected the results; (2) distributions of CGG repeats could vary among ethnic populations; (3) women with primary amenorrhea (n = 17) were included in the POI group. The last 2 possible limitations were unlikely because exclusion of data from nonwhite women or women with primary amenorrhea did not affect the results.

Published
2014

47. Dietary intake of acrylamide and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort

Author

Obon-Santacana, M. Kaaks, R. Slimani, N. Lujan-Barroso, L. and Freisling, H. Ferrari, P. Dossus, L. Chabbert-Buffet, N. and Baglietto, L. Fortner, R. T. Boeing, H. Tjonneland, A. and Olsen, A. Overvad, K. Menendez, V. Molina-Montes, E. and Larranaga, N. Chirlaque, M-D Ardanaz, E. Khaw, K-T and Wareham, N. Travis, R. C. Lu, Y. Merritt, M. A. and Trichopoulou, A. Benetou, V. Trichopoulos, D. Saieva, C. and Sieri, S. Tumino, R. Sacerdote, C. Galasso, R. and Bueno-de-Mesquita, H. B. Wirfalt, E. Ericson, U. Idahl, A. and Ohlson, N. Skeie, G. Gram, I. T. Weiderpass, E. and Onland-Moret, N. C. Riboli, E. Duell, E. J.

Abstract

Background: Three prospective studies have evaluated the association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent results. The objective of this study was to evaluate the association between acrylamide intake and EC risk: for overall EC, for type-I EC, and in never smokers and never users of oral contraceptives (OCs). Smoking is a source of acrylamide, and OC use is a protective factor for EC risk. Methods: Cox regression was used to estimate hazard ratios (HRs) for the association between acrylamide intake and EC risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Acrylamide intake was estimated from the EU acrylamide monitoring database, which was matched with EPIC questionnaire-based food consumption data. Acrylamide intake was energy adjusted using the residual method. Results: No associations were observed between acrylamide intake and overall EC (n = 1382) or type-I EC risk (n = 627). We observed increasing relative risks for type-I EC with increasing acrylamide intake among women who both never smoked and were non-users of OCs (HRQ5vsQ1: 1.97, 95% CI: 1.08-3.62; likelihood ratio test (LRT) P-value: 0.01, n = 203). Conclusions: Dietary intake of acrylamide was not associated with overall or type-I EC risk; however, positive associations with type I were observed in women who were both non-users of OCs and never smokers.

Published
2014

49. Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics : results from the EPIC cohort

Author

Ose, J., Fortner, R. T., Schock, H., Peeters, P. H., Onland-Moret, N. C., Bueno-de-Mesquita, H. B., Weiderpass, E., Gram, I. T., Overvad, K., Tjonneland, A., Dossus, L., Fournier, A., Baglietto, L., Trichopoulou, A., Benetou, V., Trichopoulos, D., Boeing, H., Masala, G., Krogh, V., Matiello, A., Tumino, R., Popovic, M., Obon-Santacana, M., Larranaga, N., Ardanaz, E., Sanchez, M-J, Menendez, V., Chirlaque, M-D, Travis, R. C., Khaw, K-T, Braendstedt, J., Idahl, Annika, Lundin, Eva, Rinaldi, S., Kuhn, E., Romieu, I., Gunter, M. J., Merritt, M. A., Riboli, E., Kaaks, R., Ose, J., Fortner, R. T., Schock, H., Peeters, P. H., Onland-Moret, N. C., Bueno-de-Mesquita, H. B., Weiderpass, E., Gram, I. T., Overvad, K., Tjonneland, A., Dossus, L., Fournier, A., Baglietto, L., Trichopoulou, A., Benetou, V., Trichopoulos, D., Boeing, H., Masala, G., Krogh, V., Matiello, A., Tumino, R., Popovic, M., Obon-Santacana, M., Larranaga, N., Ardanaz, E., Sanchez, M-J, Menendez, V., Chirlaque, M-D, Travis, R. C., Khaw, K-T, Braendstedt, J., Idahl, Annika, Lundin, Eva, Rinaldi, S., Kuhn, E., Romieu, I., Gunter, M. J., Merritt, M. A., Riboli, E., and Kaaks, R.

Abstract

Background: Prospective studies on insulin-like growth factor I (IGF-I) and epithelial ovarian cancer (EOC) risk are inconclusive. Data suggest risk associations vary by tumour characteristics. Methods: We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) to evaluate IGF-I concentrations and EOC risk by tumour characteristics (n = 565 cases). Multivariable conditional logistic regression models were used to estimate associations. Results: We observed no association between IGF-I and EOC overall or by tumour characteristics. Conclusions: In the largest prospective study to date was no association between IGF-I and EOC risk. Pre-diagnostic serum IGF-I concentrations may not influence EOC risk.

Published
2015
Full Text
View/download PDF

50. An epidemiologic risk prediction model for ovarian cancer in Europe : the EPIC study

Author

Li, K., Huesing, A., Fortner, R. T., Tjonneland, A., Hansen, L., Dossus, L., Chang-Claude, J., Bergmann, M., Steffen, A., Bamia, C., Trichopoulos, D., Trichopoulou, A., Palli, D., Mattiello, A., Agnoli, C., Tumino, R., Onland-Moret, N. C., Peeters, P. H., Bueno-de-Mesquita, H. B(as), Gram, I. T., Weiderpass, E., Sanchez-Cantalejo, E., Chirlaque, M-D, Duell, E. J., Ardanaz, E., Idahl, Annika, Lundin, E., Khaw, K-T, Travis, R. C., Merritt, M. A., Gunter, M. J., Riboli, E., Ferrari, P., Terry, K., Cramer, D., Kaaks, R., Li, K., Huesing, A., Fortner, R. T., Tjonneland, A., Hansen, L., Dossus, L., Chang-Claude, J., Bergmann, M., Steffen, A., Bamia, C., Trichopoulos, D., Trichopoulou, A., Palli, D., Mattiello, A., Agnoli, C., Tumino, R., Onland-Moret, N. C., Peeters, P. H., Bueno-de-Mesquita, H. B(as), Gram, I. T., Weiderpass, E., Sanchez-Cantalejo, E., Chirlaque, M-D, Duell, E. J., Ardanaz, E., Idahl, Annika, Lundin, E., Khaw, K-T, Travis, R. C., Merritt, M. A., Gunter, M. J., Riboli, E., Ferrari, P., Terry, K., Cramer, D., and Kaaks, R.

Abstract

Background: Ovarian cancer has a high case-fatality ratio, largely due to late diagnosis. Epidemiologic risk prediction models could help identify women at increased risk who may benefit from targeted prevention measures, such as screening or chemopreventive agents. Methods: We built an ovarian cancer risk prediction model with epidemiologic risk factors from 202 206 women in the European Prospective Investigation into Cancer and Nutrition study. Results: Older age at menopause, longer duration of hormone replacement therapy, and higher body mass index were included as increasing ovarian cancer risk, whereas unilateral ovariectomy, longer duration of oral contraceptive use, and higher number of full-term pregnancies were decreasing risk. The discriminatory power (overall concordance index) of this model, as examined with five-fold cross-validation, was 0.64 (95% confidence interval (CI): 0.57, 0.70). The ratio of the expected to observed number of ovarian cancer cases occurring in the first 5 years of follow-up was 0.90 (293 out of 324, 95% CI: 0.81-1.01), in general there was no evidence for miscalibration. Conclusion: Our ovarian cancer risk model containing only epidemiological data showed modest discriminatory power for a Western European population. Future studies should consider adding informative biomarkers to possibly improve the predictive ability of the model.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results